Had you, a year ago, possessed the foresight—or, let’s be honest, a decent tip—to invest a modest ten thousand dollars in this enterprise, you’d now be admiring fifteen thousand. A 50% return. Not bad. Though one shouldn’t mistake luck for genius. It’s merely a fortunate alignment of silicon and speculation.
Management will deliver its ritualistic quarterly accounting this week, a public recitation of numbers that obscure more than they reveal. The analysts’ conference, scheduled for Thursday at 5 p.m. ET, will be a carefully staged performance, a theater of calculated optimism. But within this spectacle, one metric demands particular scrutiny, a silent witness to the company’s enduring strength.
Uranium prices? Don’t even start me on uranium. The stuff is going parabolic, a goddamn rocket ship aimed at the stratosphere. Trading Economics says it’s up 12% in the last two months – $88.40 a pound. The highest since May. And still clawing towards that $106 peak from February. It’s a uranium frenzy, a radioactive gold rush, and Energy Fuels is… falling? Makes absolutely NO sense. NONE.
As of late morning, the shares of USA Rare Earth have ascended by twelve percent, a momentary reprieve from an earlier, more exuberant surge. The market, ever fickle, has momentarily paused its breathless climb.
One is led to consider, however, whether the ensuing years might present a more promising prospect. Let us examine the company’s declared intentions and assess the likelihood of their fulfillment. It is a matter of discerning whether their current course will lead to a respectable stability, or merely a continuation of past disappointments.
The implications of this, should everything proceed according to plan (a concept statistically less likely than a penguin winning the Kentucky Derby), could be…significant. Upside, as the financial community so elegantly puts it, could be “massive.” One wonders, though, if “massive” is really the best descriptor. Perhaps “sufficiently large to require a new unit of measurement” would be more accurate. (One has considered proposing the “Bartholomew” – equivalent to 1.42 billion dollars, after careful consideration of the average lifespan of a garden gnome – but the paperwork involved is, frankly, terrifying.)
Now, I’m a historian, which means I’m supposed to be objective. But let’s be honest, I’m also a sucker for a good story. And in my search for companies worthy of my (totally imaginary) Voyager Portfolio, I stumbled upon something…unexpected. Biotech is usually a minefield, full of promises and pink slips. But Harmony Biosciences (HRMY +0.04%)? This little company…it’s got a pulse. And maybe, just maybe, a plot twist. It’s not a household name, which is suspicious in itself. I mean, everyone’s heard of Big Pharma, right? These guys? Radio silence. That’s what made me investigate. This first article is the beginning of a three-part series, so buckle up. It’s going to be a bumpy, and hopefully profitable, ride.
Four years of navigating the tempestuous seas of market cycles, of chasing the ever-elusive “venture scale,” have led to this moment. Unlike the many projects that vanish into the ether, Entropy exits with a modicum of dignity, returning capital to its investors. A rare gesture in a world where greed often trumps grace.
AMD, a company once content to dwell in the shadows of its larger rival, now fancies itself a leading man. Its data center chips, though still trailing Nvidia in the grand scheme, are experiencing a surge in demand. The third quarter, we are told, saw record sales of its EPYC processors, driven by the insatiable appetites of Google, Microsoft, and even Alibaba. A flattering report, certainly, but one must ask: is this genuine appreciation, or merely a temporary indulgence?
These instruments, ostensibly dedicated to the pursuit of low-risk income through the acquisition of U.S. Treasury obligations, represent a peculiar paradox. They are, in essence, a formalized admission of systemic fragility—a recognition that the pursuit of unbridled growth necessitates the concurrent construction of elaborate bulwarks against its inevitable failures. The conservative investor, it appears, is not seeking prosperity, but rather the postponement of reckoning.